AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use

AstraZeneca (AZN) announced that the FDA has approved its blockbuster cancer drug Imfinzi (durvalumab) plus chemotherapy, followed by Imfinzi monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer.The approval for expanded use of Imfinzi was based on data from a prespecified exploratory subgroup analysis by MMR status in the phase III DUO-E study.Data from the study showed that treatment with Imfinzi in combination with carboplatin and ...